Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1352077rdf:typepubmed:Citationlld:pubmed
pubmed-article:1352077lifeskim:mentionsumls-concept:C0086661lld:lifeskim
pubmed-article:1352077lifeskim:mentionsumls-concept:C0024305lld:lifeskim
pubmed-article:1352077lifeskim:mentionsumls-concept:C1515670lld:lifeskim
pubmed-article:1352077pubmed:issue1lld:pubmed
pubmed-article:1352077pubmed:dateCreated1992-7-29lld:pubmed
pubmed-article:1352077pubmed:abstractTextSteady state c-myc mRNA levels determined by Northern blot analysis were examined in non-Hodgkin's lymphomas (NHL) of both high (n = 29) and low malignancy (n = 18), and in non-specific chronic lymphadenitis (n = 6). High grade NHL, classified according to the updated Kiel classification, revealed significantly larger amounts of c-myc mRNA compared with low grade NHL and lymphadenitis. mRNA levels in non-specific lymphadenitis were lower than in low grade NHL, but the differences were not statistically significant. No correlation between c-myc mRNA levels and the immunologic phenotype was discernible. Growth fractions of the NHL were determined by immunostaining with the monoclonal antibody Ki-67. Significant correlations between the percentages of Ki-67-positive cells, as well as the amounts of c-myc mRNA, and classification into high or low grade NHL were found. However, the percentage of Ki-67 positive cells and c-myc mRNA levels in individual cases and in the various histologic entities of NHL did not correlate. Our results indicate the overexpression of the c-myc gene in NHL, and a highly significant correlation of steady state c-myc mRNA levels with the prognosis-related histomorphologic Kiel classification of NHL into different subgroups of low and high grade malignancy.lld:pubmed
pubmed-article:1352077pubmed:languageenglld:pubmed
pubmed-article:1352077pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1352077pubmed:citationSubsetIMlld:pubmed
pubmed-article:1352077pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1352077pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1352077pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1352077pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1352077pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1352077pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1352077pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1352077pubmed:statusMEDLINElld:pubmed
pubmed-article:1352077pubmed:issn0340-6075lld:pubmed
pubmed-article:1352077pubmed:authorpubmed-author:Radaszkiewicz...lld:pubmed
pubmed-article:1352077pubmed:authorpubmed-author:HöflerHHlld:pubmed
pubmed-article:1352077pubmed:authorpubmed-author:LehmacherWWlld:pubmed
pubmed-article:1352077pubmed:authorpubmed-author:FellbaumCClld:pubmed
pubmed-article:1352077pubmed:authorpubmed-author:PützBBlld:pubmed
pubmed-article:1352077pubmed:authorpubmed-author:RuhriCClld:pubmed
pubmed-article:1352077pubmed:issnTypePrintlld:pubmed
pubmed-article:1352077pubmed:volume62lld:pubmed
pubmed-article:1352077pubmed:geneSymbolc-myclld:pubmed
pubmed-article:1352077pubmed:geneSymbolN-myclld:pubmed
pubmed-article:1352077pubmed:ownerNLMlld:pubmed
pubmed-article:1352077pubmed:authorsCompleteYlld:pubmed
pubmed-article:1352077pubmed:pagination61-8lld:pubmed
pubmed-article:1352077pubmed:dateRevised2007-11-15lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:meshHeadingpubmed-meshheading:1352077-...lld:pubmed
pubmed-article:1352077pubmed:year1992lld:pubmed
pubmed-article:1352077pubmed:articleTitlec-myc mRNA expression in non-Hodgkin's lymphomas.lld:pubmed
pubmed-article:1352077pubmed:affiliationInstitute of Pathology, Technische Universität München, School of Medicine, Federal Republic of Germany.lld:pubmed
pubmed-article:1352077pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1352077pubmed:publicationTypeComparative Studylld:pubmed